Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

NCT02000622 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02000622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02000622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
March 27, 2014
Completion date
December 23, 2025
Enrollment
302 (actual)
Sites
171

Conditions

As the registry lists them; a condition with its own page is linked.

brca 1 gene mutation, brca 2 gene mutation, breast cancer metastatic